Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1

BACKGROUND: Oncolytic viruses preferentially replicate in tumors as compared to normal tissue and promote immunogenic cell death and induction of host systemic anti-tumor immunity. HSV-1 was chosen for further development as an oncolytic immunotherapy in this study as it is highly lytic, infects hum...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Suzanne, Kuncheria, Linta, Roulstone, Victoria, Kyula, Joan N., Mansfield, David, Bommareddy, Praveen K., Smith, Henry, Kaufman, Howard L., Harrington, Kevin J., Coffin, Robert S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6689178/
https://www.ncbi.nlm.nih.gov/pubmed/31399043
http://dx.doi.org/10.1186/s40425-019-0682-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6689178/
https://www.ncbi.nlm.nih.gov/pubmed/31399043
http://dx.doi.org/10.1186/s40425-019-0682-1

Ejemplares similares